EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long‐Term Multicentre Real‐World Study

Reineke Soegiharto iD, Esther Van der Wind, Mehran Alizadeh Aghdam iD, Jennifer A Sørensen, Esmee Van Lindonk, Ferhan Bulut Demir, Nasser Mohammad Porras, Yoshimi Matsuo, Lea Kiefer, André C Knulst, Marcus Maurer, Carla Ritchie und 16 weitere

Clinical & Experimental Allergy · 2025

DOI: 10.1111/cea.70067 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical & Experimental Allergy, 2025. Verfasst von Reineke Soegiharto und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology/Allergology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Anti-Allergic Agents, Urticaria. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic urticaria (CU) treatment with omalizumab is considered safe in short‐term studies. Large real‐world studies focusing on the long‐term safety of omalizumab and associated factors are lacking. We aimed to investigate the spectrum of reported side effects in omalizumab‐treated CU patients in a large long‐term daily practice cohort.

Methods

A multinational multicentre retrospective study was conducted at 14 specialised urticaria centres (UCAREs), including all CU patients ever treated with omalizumab until centre‐specific data lock. The prevalence of patient‐reported side effects was assessed.

Results

A total of 1859 patients were included, of which 32.9% ( n = 612) reported side effects during omalizumab treatment with a wide range across centres (0%–75.5%). Fatigue (15.8%, n = 293), headache (11.6%, n = 215) and flu‐like symptoms (9.3%, n = 172) were most common. No events suggestive of anaphylaxis and no new notably prevalent side effects were reported. Hair loss was reported by 2.9% ( n = 53/1859) of patients, leading to treatment adjustment in 21.1% ( n = 8/38 with sufficient data). Patients who reported side effects were more often female (78.3% vs. 68.6%, p < 0.001), had worse disease control prior to omalizumab (Urticaria Control Test, UCT, 4.0 vs. 6.0, p < 0.001), and lower fast response (Weekly Urticaria Activity Score, UAS7, < 7 or UCT > 11 within 4 weeks, 42.6% vs. 59.5%, p < 0.001) and complete/good response rates (UAS7 < 7 or UCT > 11 at end of treatment, 72.3% vs. 84.4%, p < 0.001) compared to patients without side effects. While only 2.4% ( n = 44/1859) of patients discontinued treatment due to side effects, 5.5% ( n = 100/1859) and 12.8% ( n = 238/1859) of patients reporting side effects with insufficient (UAS7 ≥ 7 or UCT 3–11 at end of treatment) and complete/good response, respectively, remained on omalizumab.

Conclusions

The safety and tolerability of omalizumab was confirmed. Notably, the wide variation in reported side effects across centres suggests that differences in awareness influence reporting. Hair loss was more prevalent than described before, warranting extra attention. Side effects were more often reported in patients whose characteristics suggest reduced effectiveness of omalizumab, possibly related to a negative association with omalizumab and suggesting increased disease burden. Availability of new therapies might increase the impact of side effects on treatment decisions, not only in omalizumab‐refractory patients but potentially even among good responders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabChronic UrticariaAnti-Allergic AgentsUrticariaHumansFemaleMaleMiddle AgedAdultRetrospective StudiesAgedYoung AdultTreatment OutcomeAdolescent

Stichwörter der Autor:innen

IgEangioedemadermatologymast Cellsmulticentrenoceboomalizumabside effectsurticaria

Substanzen

OmalizumabAnti-Allergic Agents

Autor:innen und Institutionen

  • Department of Dermatology/Allergology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Department of Dermato-Venereology and Wound Healing Centre, University of Copenhagen, Bispebjerg Hospital, Copenhagen, Denmark.
  • Department of Dermatology, Erasmus MC, Rotterdam, the Netherlands.
  • Department of Dermatology, Marmara University School of Medicine, İstanbul, Turkey.
  • Department of Dermatology, Hospital del Mar Research Institute. Universitat Pompeu Fabra de Barcelona, Barcelona, Spain.
  • Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

ORCID-Profile: Reineke Soegiharto, Mehran Alizadeh Aghdam, Rabia Oztas Kara

Förderung

  • Novartis Pharma

Zitieren

APA

Soegiharto, R., Van der Wind, E., Alizadeh Aghdam, M., Sørensen, J. A., Van Lindonk, E., Bulut Demir, F., Mohammad Porras, N., Matsuo, Y., Kiefer, L., Knulst, A. C., Maurer, M., Ritchie, C., Rudenko, M., Kocatürk, E., Fachini Jardim Criado, R., Gregoriou, S., Bobylev, T., Kleinheinz, A., Takahagi, S., …, & Röckmann, H. (2025). Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long‐Term Multicentre Real‐World Study. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.70067

Vancouver

Soegiharto R, Van der Wind E, Alizadeh Aghdam M, Sørensen JA, Van Lindonk E, Bulut Demir F, et al. Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long‐Term Multicentre Real‐World Study. Clinical & Experimental Allergy. 2025. doi:10.1111/cea.70067

BibTeX
@article{Soegiharto2025,
  author = {Soegiharto, Reineke and Van der Wind, Esther and Alizadeh Aghdam, Mehran and Sørensen, Jennifer A and Van Lindonk, Esmee and Bulut Demir, Ferhan and Mohammad Porras, Nasser and Matsuo, Yoshimi and Kiefer, Lea and Knulst, André C and Maurer, Marcus and Ritchie, Carla and Rudenko, Michael and Kocatürk, Emek and Fachini Jardim Criado, Roberta and Gregoriou, Stamatis and Bobylev, Tatjana and Kleinheinz, Andreas and Takahagi, Shunsuke and Hide, Michihiro and Giménez-Arnau, Ana M and Salman, Andaç and Oztas Kara, Rabia and Sevimli Dikicier, Bahar and Van Doorn, Martijn B A and Thomsen, Simon F and Van den Reek, Juul M P A and Röckmann, Heike},
  title = {Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long‐Term Multicentre Real‐World Study},
  journal = {Clinical & Experimental Allergy},
  year = {2025},
  doi = {10.1111/cea.70067}
}
Kostenlos starten →